Download MendeleyStructure-based identification of a G protein-biased allosteric modulator of cannabinoid receptor CB1.
Shen, S., Wu, C., Lin, G., Yang, X., Zhou, Y., Zhao, C., Miao, Z., Tian, X., Wang, K., Yang, Z., Liu, Z., Guo, N., Li, Y., Xia, A., Zhou, P., Liu, J., Yan, W., Ke, B., Yang, S., Shao, Z.(2024) Proc Natl Acad Sci U S A 121: e2321532121-e2321532121
- PubMed: 38830102
- DOI: https://doi.org/10.1073/pnas.2321532121
- Primary Citation of Related Structures:
8IKG, 8IKH - PubMed Abstract:
Cannabis sativa is known for its therapeutic benefit in various diseases including pain relief by targeting cannabinoid receptors. The primary component of cannabis, Δ9-tetrahydrocannabinol (THC), and other agonists engage the orthosteric site of CB1, activating both Gi and β-arrestin signaling pathways. The activation of diverse pathways could result in on-target side effects and cannabis addiction, which may hinder therapeutic potential. A significant challenge in pharmacology is the design of a ligand that can modulate specific signaling of CB1. By leveraging insights from the structure-function selectivity relationship (SFSR), we have identified Gi signaling-biased agonist-allosteric modulators (ago-BAMs). Further, two cryoelectron microscopy (cryo-EM) structures reveal the binding mode of ago-BAM at the extrahelical allosteric site of CB1. Combining mutagenesis and pharmacological studies, we elucidated the detailed mechanism of ago-BAM-mediated biased signaling. Notably, ago-BAM CB-05 demonstrated analgesic efficacy with fewer side effects, minimal drug toxicity and no cannabis addiction in mouse pain models. In summary, our finding not only suggests that ago-BAMs of CB1 provide a potential nonopioid strategy for pain management but also sheds light on BAM identification for GPCRs.
Organizational Affiliation:
Division of Nephrology and Kidney Research Institute, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu 610041, Sichuan, China.
